Collaborative Arrangement, Rights and Obligation, Expected Timing of Satisfaction, Period

No definition available.

Name:	surf_CollaborativeArrangementRightsAndObligationExpectedTimingOfSatisfactionPeriod
Namespace Prefix:	surf_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement milestone payments.

+ References

No definition available.

+ Details

Name:	surf_CollaborativeArrangementRightsAndObligationsAggregateMilestonePayments
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

ollaborative Arrangement, Rights and Obligations, Upfront License Execution Fee

+ References

No definition available.

+ Details

Name:	surf_CollaborativeArrangementRightsAndObligationsUpfrontLicenseExecutionFee
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement option fee percentage.

+ References

No definition available.

+ Details

Name:	surf_LicenseAgreementOptionFeePercentage
Namespace Prefix:	surf_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement technical milestone payment upon achievement.

+ References

No definition available.

+ Details

Name:	surf_LicenseAgreementTechnicalMilestonePaymentUponAchievement
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=surf_AdimabLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=surf_MemorialSloanKetteringCancerCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=surf_VaccinexIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_ClinicalMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_RegulatoryMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Mar. 31, 2021	Nov. 30, 2020	Jul. 31, 2014	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
License Agreements
Research and development				$ 67,003	$ 53,572	$ 41,018
Adimab LLC
License Agreements
Option fee percentage			65.00%
Adimab LLC \| License Agreements
License Agreements
Research and development				0	3,000	3,092
Adimab LLC \| Maximum
License Agreements
Technical milestones payment			$ 250
License agreement milestone payments			$ 13,000
MSK \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
License Agreements
License agreement milestone payments		$ 7,500
Research and development				$ 200	50	$ 50
Upfront license execution fee due		$ 100
Timing of satisfaction				10 years
Vaccinex, Inc. \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
License Agreements
Research and development				$ 500	$ 850
Payments to related party				$ 850
Vaccinex, Inc. \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Clinical Milestone Payment
License Agreements
License agreement milestone payments	$ 3,500
Vaccinex, Inc. \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Regulatory Milestone Payment
License Agreements
License agreement milestone payments	$ 11,500